You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

325 Results
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Oct 2023
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Regimen
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Palliative
Apr 2023
Regimen
Intent: Palliative
Apr 2023
Regimen
Intent: Palliative
Apr 2023
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate),
riTUXimab (Unfunded)
Nov 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to specific criteria.
Feb 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
Aug 2023

Pages